Radiation-induced fibrosis treatment sales will grow through 2036, led by pharmaceuticals at 55% of the product segment in 2026. The market was valued at USD 79.0 million in 2025 and is expected to be worth USD 153.1 million by 2036, creating an incremental opportunity of USD 69.2 million.